Americas · Regional markets · Financial Post
Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
NEW YORK — Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying…
Read the full article on Financial Post Sign in to saveMarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (financialpost.com)





